Skip to main content
SpringerLink
Log in

Radiation Therapy for Hodgkin Lymphoma and Other Hematopoietic Disorders

  • Chapter
  • First Online:
Technical Basis of Radiation Therapy

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

Abstract

Hematologic malignancies involve the blood, bone marrow or lymph nodes including Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma, Myeloma, and Leukemias. Extensive research over the past two decades has led to an explosion of new therapies resulting in improvement in outcomes. Radiation therapy continues to play a paramount role in the therapy of many hematologic malignancies, whether as definitive therapy, as consolidation after chemotherapy, as part of bone marrow transplantation protocols, or as palliation. During the past two decades, significant advances in radiation therapy have occurred, including the development of involved-node radiation therapy and the adoption of conformal radiation administration. It is expected that modern techniques will reduce the long-term sequelae associated with radiation-based treatments. This review will discuss the current role of radiation therapy, focusing especially on Hodgkin’s Lymphoma and to a lesser extent on Non-Hodgkin’s Lymphoma and plasmacytoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aleman BM, Raemaekers JM, Tirelli U et al (2003a) Involved-field radiation therapy for advanced Hodgkin’s lymphoma. N Engl J Med 348(24):2396–2406

    Article  PubMed  Google Scholar 

  • Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE (2003b) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21(18):3431–3439

    Article  PubMed  Google Scholar 

  • Aleman BM, Raemaekers JM, Tomisic R et al (2007) Involved-field radiation therapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 67(1):19–30

    Article  PubMed  Google Scholar 

  • Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19(4):453–473

    Article  PubMed  CAS  Google Scholar 

  • Anagnostopoulos I, Hansmann ML, Franssila K et al (2000) European task force on lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96(5):1889–1899

    PubMed  CAS  Google Scholar 

  • Ashton-Key M, Thorpe PA, Allen JP, Isaacson PG (1995) Follicular Hodgkin’s disease. Am J Surg Pathol 19(11):1294–1299

    Article  PubMed  CAS  Google Scholar 

  • Backstrand KH, Ng AK, Takvorian RW et al (2001) Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin’s disease. J Clin Oncol 19(3):736–741

    PubMed  CAS  Google Scholar 

  • Ballova V, Ruffer JU, Haverkamp H et al (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16(1):124–131

    Article  PubMed  CAS  Google Scholar 

  • Bangerter M, Moog F, Buchmann I et al (1998) Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 9(10):1117–1122

    Article  PubMed  CAS  Google Scholar 

  • Barrington SF, Qian W, Somer EJ et al (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37(10):1824–1833

    Article  PubMed  Google Scholar 

  • Belkacémi Y, Zouhair A, Ozsahin M et al (2006) Prognostic factors and management of rare cancers. Cancer Radiother 10:323–329

    Article  PubMed  Google Scholar 

  • Bernstein SH, Burack WR (2009) The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 532–541

    Google Scholar 

  • Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT (1997) Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 37(1):67–73

    Article  PubMed  CAS  Google Scholar 

  • Biti GP, Cimino G, Cartoni C et al (1992) Extended-field radiation therapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10(3):378–382

    PubMed  CAS  Google Scholar 

  • Boleti E, Johnson PW (2007) Primary mediastinal B-cell lymphoma. Hematol Oncol 25:157–163

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiation therapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22(14):2835–2841

    Article  PubMed  Google Scholar 

  • Buchmann I, Reinhardt M, Elsner K et al (2001) 2-(fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91(5):889–899

    Article  PubMed  CAS  Google Scholar 

  • Burke HB, Henson DE (1993) The American joint committee on cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 72(10):3131–3135

    Article  PubMed  CAS  Google Scholar 

  • Campbell B, Wirth A, Milner A, Di Iulio J, MacManus M, Ryan G (2005) Long-term follow-up of salvage radiation therapy in Hodgkin’s lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys 63(5):1538–1545

    Article  PubMed  Google Scholar 

  • Campbell BA, Voss N, Pickles T et al (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26(32):5170–5174

    Article  PubMed  Google Scholar 

  • Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31(11):1860–1861

    PubMed  CAS  Google Scholar 

  • Carde P, Hagenbeek A, Hayat M et al (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European organization for research and treatment of cancer lymphoma cooperative group. J Clin Oncol 11(11):2258–2272

    PubMed  CAS  Google Scholar 

  • Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin’s disease. An analysis of technique, tumor eradication, and complications. Cancer 37(6):2813–2825

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 17(4):1244

    PubMed  CAS  Google Scholar 

  • Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  • Coia LR, Hanks GE (1988) Complications from large field intermediate dose infradiaphragmatic radiation: an analysis of the patterns of care outcome studies for Hodgkin’s disease and seminoma. Int J Radiat Oncol Biol Phys 15(1):29–35

    Article  PubMed  CAS  Google Scholar 

  • Cosset JM, Henry-Amar M, Meerwaldt JH (1991) Long-term toxicity of early stages of Hodgkin’s disease therapy: the EORTC experience. EORTC lymphoma cooperative group. Ann Oncol 2(Suppl 2):77–82

    Article  PubMed  Google Scholar 

  • De Bruin ML, Dorresteijn LD, van’t Veer MB et al (2009a) Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101(13):928–937

    Article  PubMed  Google Scholar 

  • De Bruin ML, Sparidans J, van’t Veer MB et al (2009b) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27(26):4239–4246

    Article  PubMed  Google Scholar 

  • de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 12(1):29–37

    Article  PubMed  Google Scholar 

  • Diehl V, Loeffler M, Pfreundschuh M et al (1995) Further chemotherapy versus low-dose involved-field radiation therapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin’s disease. German Hodgkins’ Study Group (GHSG). Ann Oncol 6(9):901–910

    PubMed  CAS  Google Scholar 

  • Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin’s disease. J Clin Oncol 17(3):776–783

    PubMed  CAS  Google Scholar 

  • Diehl V, Haverkamp H, Mueller RP et al (2008) Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiation therapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the randomised HD12 trial of the German Hodgkin Study Group (GHSG). Blood 112:(11) [Abstract 1558]

    Google Scholar 

  • Diller L, Medeiros Nancarrow C, Shaffer K et al (2002) Breast cancer screening in women previously treated for Hodgkin’s disease: a prospective cohort study. J Clin Oncol 20(8):2085–2091

    Article  PubMed  Google Scholar 

  • Dimopoulos MA, Moulopoulos A, Delasalle K et al (1992) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Hematol Oncol Clin North Am 6:359–369

    PubMed  CAS  Google Scholar 

  • Donaldson SS, Link MP (1987) Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin’s disease. J Clin Oncol 5(5):742–749

    PubMed  CAS  Google Scholar 

  • Duhmke E, Diehl V, Loeffler M et al (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiation therapy alone. Int J Radiat Oncol Biol Phys 36(2):305–310

    Article  PubMed  CAS  Google Scholar 

  • Eich HT, Müller RP, Engenhart-Cabillic R, Lukas P, Schmidberger H et al (2008) Involved-node radiation therapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184(8):406–410

    Article  PubMed  Google Scholar 

  • Eich HT, Diehl V, Gorgen H et al (2010) Intensified chemotherapy and dose-reduced involved-field radiation therapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28(27):4199–4206

    Article  PubMed  Google Scholar 

  • Elstrom R, Guan L, Baker G et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101(10):3875–3876

    Article  PubMed  CAS  Google Scholar 

  • Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122

    Article  PubMed  CAS  Google Scholar 

  • Engert A, Schiller P, Josting A et al (2003) Involved-field radiation therapy is equally effective and less toxic compared with extended-field radiation therapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21(19):3601–3608

    Article  PubMed  Google Scholar 

  • Engert A, Franklin J, Eich HT et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiation therapy is superior to radiation therapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25(23):3495–3502

    Article  PubMed  CAS  Google Scholar 

  • Engert A, Diehl V, Franklin J et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554

    Article  PubMed  Google Scholar 

  • Engert A, Plutschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652

    Article  PubMed  CAS  Google Scholar 

  • Fabian CJ, Mansfield CM, Dahlberg S et al (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A southwest oncology group randomized study. Ann Intern Med 120(11):903–912

    PubMed  CAS  Google Scholar 

  • Ferme C, Mounier N, Casasnovas O et al (2006) Long-term results and competing risk analysis of the H89 trial in patients with advanced stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 107(12):4636–4642

    Article  PubMed  CAS  Google Scholar 

  • Ferme C, Eghbali H, Meerwaldt JH et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357(19):1916–1927

    Article  PubMed  CAS  Google Scholar 

  • Fletcher GH, Shukovsky LJ (1975) The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl 56(5):383–400

    PubMed  CAS  Google Scholar 

  • Franklin J, Pluetschow A, Paus M et al (2006) Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 17(12):1749–1760

    Article  PubMed  CAS  Google Scholar 

  • Franklin J, Paus M, Pluetschow A, Specht L (2009) Chemotherapy, radiation therapy and combined modality for Hodgkin’s disease, with emphasis on second cancer risk. Wiley, New York

    Google Scholar 

  • Frassica DA, Frassica FJ, Schray MF et al (1989) Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 16:43–48

    Article  PubMed  CAS  Google Scholar 

  • Friedberg JW, Fischman A, Neuberg D et al (2004) FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 45(1):85–92

    Article  PubMed  Google Scholar 

  • Front D, Israel O (1995) The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 25(1):60–71

    Article  PubMed  CAS  Google Scholar 

  • Gale RP, Butturini A, Bortin MM (1991) What does total body irradiation do in bone marrow transplants for leukemia? Int J Radiat Oncol Biol Phys 20:631–634

    Article  PubMed  CAS  Google Scholar 

  • Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746–3752

    Article  PubMed  CAS  Google Scholar 

  • Gilbert R (1925) La roentgentherapie de la granulomatose maligne. J Radiol Electrol 9:509–514

    Google Scholar 

  • Gilbert R (1939) Radiation therapy in Hodgkin’s disease (malignant granulomatosis). Am J Roentgenol 41:198–241

    Google Scholar 

  • Gilbert R, Babaiantz L (1931) Notre Methode De Roentgentherapie De La Lymphogranulomatoses (Hodgkin): Resultats Eloignes. Acta Radiol 12:523–529

    Article  Google Scholar 

  • Ginzton EL, Mallory KB, Kaplan HS (1957) The Stanford medical linear accelerator. I. Design and development. Stanford Med Bull 15(3):123–140

    PubMed  CAS  Google Scholar 

  • Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiation therapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79(3):270–277

    Article  PubMed  Google Scholar 

  • Girinsky T, Specht L, Ghalibafian M et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88(2):202–210

    Article  PubMed  Google Scholar 

  • Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P (1998) Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 46(1):51–62

    Article  PubMed  CAS  Google Scholar 

  • Goodman KA, Toner S, Hunt M, Wu EJ, Yahalom J (2005) Intensity-modulated radiation therapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62(1):198–206

    Article  PubMed  Google Scholar 

  • Gospodarowicz MK, Henson DE, Hutter RVP, O’Sullivan B, Sobin LH, Wittekind C (2001) Prognostic Factors in Cancer, 2nd edn. Wiley-Liss, New York

    Google Scholar 

  • Haas RL, Poortmans P, de Jong D et al (2003) High response rates and lasting remissions after low-dose involved field radiation therapy in indolent lymphomas. J Clin Oncol 21:2474–2480

    Article  PubMed  CAS  Google Scholar 

  • Haas RL, Poortmans P, de Jong D et al (2005) Effective palliation by low dose local radiation therapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer 41:1724–1730

    Article  PubMed  CAS  Google Scholar 

  • Haas RL, Girinsky T, Aleman BM et al (2009) Low-dose involved-field radiation therapy as alternative treatment of nodular lymphocyte predominance Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 74:1199–1202

    Article  PubMed  Google Scholar 

  • Haioun C, Lepage E, Gisselbrecht C et al (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol–a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18(16):3025–3030

    PubMed  CAS  Google Scholar 

  • Hancock SL, Hoppe RT (1996) Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 6(3):225–242

    Article  PubMed  Google Scholar 

  • Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270(16):1949–1955

    Article  PubMed  CAS  Google Scholar 

  • Hanks GE, Kinzie JJ, White RL, Herring DF, Kramer S (1983) Patterns of care outcome studies. Results of the national practice in Hodgkin’s disease. Cancer 51(4):569–573

    Article  PubMed  CAS  Google Scholar 

  • Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5):1361–1392

    PubMed  CAS  Google Scholar 

  • Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835–3849

    PubMed  CAS  Google Scholar 

  • Haybittle JL, Hayhoe FG, Easterling MJ et al (1985) Review of British National lymphoma investigation studies of Hodgkin’s disease and development of prognostic index. Lancet 1(8435):967–972

    Article  PubMed  CAS  Google Scholar 

  • Henry-Amar M, Friedman S, Hayat M et al (1991) Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med 114(5):361–365

    PubMed  CAS  Google Scholar 

  • Herbst C, Rehan FA, Brillant C et al (2010) Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica 95(3):494–500

    Article  PubMed  CAS  Google Scholar 

  • Hodgson DC, Koh ES, Tran TH et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110(11):2576–2586

    Article  PubMed  Google Scholar 

  • Hoppe RT (ed) (1993) Hodgkin’s Disease: Patterns of care study newsletter, 1990–1991. American College of Radiology, Philadelphia

    Google Scholar 

  • Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982) The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59(3):455–465

    PubMed  CAS  Google Scholar 

  • Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA (1988) Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 6(12):1822–1831

    PubMed  CAS  Google Scholar 

  • Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA (2002) Stanford V and radiation therapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20(3):630–637

    Article  PubMed  Google Scholar 

  • Hueltenschmidt B, Sautter-Bihl ML, Lang O et al (2001) Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 91(2):302–310

    Article  PubMed  CAS  Google Scholar 

  • Hutchings M, Barrington SF (2009) PET/CT for therapy response assessment in lymphoma. J Nucl Med 50(Suppl 1):21S–30S

    Article  PubMed  CAS  Google Scholar 

  • Hutchings M, Eigtved AI, Specht L (2004) FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52(1):19–32

    Article  PubMed  Google Scholar 

  • Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52–59

    Article  PubMed  CAS  Google Scholar 

  • Ifrah N, Hunault M, Jais JP et al (1996) Infradiaphragmatic Hodgkin’s disease: long term results of combined modality therapy. Leuk Lymphoma 21(1–2):79–84

    Article  PubMed  CAS  Google Scholar 

  • Isasi CR, Lu P, Blaufox MD (2005) A meta-analysis of 18F–2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104(5):1066–1074

    Article  PubMed  Google Scholar 

  • Itti E, Lin C, Dupuis J et al (2009) Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50(4):527–533

    Article  PubMed  Google Scholar 

  • Jackson H, Parker F (1944a) Hodgkin’s Disease II. Pathology. N Engl J Med 231:35–44

    Google Scholar 

  • Jackson H, Parker F (1944b) Hodgkin’s Disease I. General considerations. N Engl J Med 230:1–8

    Article  Google Scholar 

  • Jerusalem G, Warland V, Najjar F et al (1999a) Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl Med Commun 20(1):13–20

    Article  PubMed  CAS  Google Scholar 

  • Jerusalem G, Beguin Y, Fassotte MF et al (1999b) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94(2):429–433

    PubMed  CAS  Google Scholar 

  • Jerusalem G, Beguin Y, Fassotte MF et al (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14(1):123–130

    Article  PubMed  CAS  Google Scholar 

  • Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP (2010) Consolidation radiation therapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 28(20):3352–3359

    Article  PubMed  Google Scholar 

  • Josting A, Nogova L, Franklin J et al (2005) Salvage radiation therapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin lymphoma study group. J Clin Oncol 23(7):1522–1529

    Article  PubMed  Google Scholar 

  • Kaplan HS (1962) The radical radiation therapy of regionally localized Hodgkin’s disease. Radiol 78:553–561

    CAS  Google Scholar 

  • Kelly KM, Hutchinson RJ, Sposto R et al (2002) Feasibility of upfront dose-intensive chemotherapy in children with advanced stage Hodgkin’s lymphoma: preliminary results from the Children’s Cancer Group Study CCG-59704. Ann Oncol 13(Suppl 1):107–111

    Article  PubMed  Google Scholar 

  • Knobel David, Zouhair Abderrahim, Tsang Richard W et al (2006) Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 6:118

    Article  PubMed  Google Scholar 

  • Knowling MA, Harwood AR, Bergsagel DE (1983) Comparison of extra medullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1:255–262

    PubMed  CAS  Google Scholar 

  • Koh ES, Sun A, Tran TH et al (2006) Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 66(1):223–228

    Article  PubMed  Google Scholar 

  • Kostakoglu L (2008) Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 35(8):1413–1420

    Article  PubMed  Google Scholar 

  • Laskar S, Gupta T, Vimal S et al (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22(1):62–68

    Article  PubMed  CAS  Google Scholar 

  • Lee CK, Bloomfield CD, Goldman AI, Levitt SH (1980) Prognostic significance of mediastinal involvement in Hodgkin’s disease treated with curative radiation therapy. Cancer 46(11):2403–2409

    Article  PubMed  CAS  Google Scholar 

  • Lee CK, Aeppli DM, Bloomfield CD, Levitt SH (1990) Curative radiation therapy for laparotomy-staged IA, IIA, IIIA Hodgkin’s disease: an evaluation of the gains achieved with radical radiation therapy. Int J Radiat Oncol Biol Phys 19(3):547–559

    Article  PubMed  CAS  Google Scholar 

  • Leibenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA (1989) Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin’s disease. J Clin Oncol 7(1):81–91

    PubMed  CAS  Google Scholar 

  • Levitt SH, Purdy JA, Perez CA, Vijayakumar S (2006) Technical basis of radiation therapy: Practical clinical applications, 4th edn. Springer, New York

    Book  Google Scholar 

  • Liebross RH, Ha CS, Cox JD et al (1999) Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 52:245–249

    Article  PubMed  CAS  Google Scholar 

  • Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7(11):1630–1636

    PubMed  CAS  Google Scholar 

  • Loeffler M, Diehl V, Pfreundschuh M et al (1997) Dose-response relationship of complementary radiation therapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin’s disease. J Clin Oncol 15(6):2275–2287

    PubMed  CAS  Google Scholar 

  • Longo DL, Young RC, Wesley M et al (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4(9):1295–1306

    PubMed  CAS  Google Scholar 

  • Longo DL, Glatstein E, Duffey PL et al (1991) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol 9(6):906–917

    PubMed  CAS  Google Scholar 

  • Lukes RJ, Butler JJ (1966) The pathology and nomenclature of Hodgkin’s disease. Cancer Res 26(6):1063–1083

    PubMed  CAS  Google Scholar 

  • Mac Manus MP, Hoppe RT (1996) Is radiation therapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282–1290

    PubMed  CAS  Google Scholar 

  • Macdonald DA, Ding K, Gospodarowicz MK et al (2007) Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 18(10):1680–1684

    Article  PubMed  CAS  Google Scholar 

  • Mai DH, Peschel RE, Portlock C, Knowlton A, Farber L (1991) Stage I and II subdiaphragmatic Hodgkin’s disease. Cancer 68(7):1476–1481

    Article  PubMed  CAS  Google Scholar 

  • Mauch PM (1994) Controversies in the management of early stage Hodgkin’s disease. Blood 83(2):318–329

    PubMed  CAS  Google Scholar 

  • Mauch P, Ng A, Aleman B et al (2005) Report from the Rockefellar foundation sponsored international workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin’s disease, Bellagio, Italy, 9–16 July 2003. Eur J Haematol 66:68–76

    Google Scholar 

  • Mauch P, Greenberg H, Lewin A, Cassady JR, Weichselbaum R, Hellman S (1983) Prognostic factors in patients with subdiaphragmatic Hodgkin’s disease. Hematol Oncol 1(3):205–214

    Article  PubMed  CAS  Google Scholar 

  • Mauch P, Tarbell N, Weinstein H et al (1988) Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and para-aortic irradiation. J Clin Oncol 6(10):1576–1583

    PubMed  CAS  Google Scholar 

  • Mauch P, Larson D, Osteen R et al (1990) Prognostic factors for positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol 8(2):257–265

    PubMed  CAS  Google Scholar 

  • Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S (1993) Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 71(6):2062–2071

    Article  PubMed  CAS  Google Scholar 

  • Mauch PM, Kalish LA, Marcus KC et al (1995) Long-term survival in Hodgkin’s disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1(1):33–42

    PubMed  CAS  Google Scholar 

  • Meignan M, Gallamini A, Haioun C, Polliack A (2010) Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma 51(12):2171–2180

    Google Scholar 

  • Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50(8):1257–1260

    Article  PubMed  Google Scholar 

  • Meyer RM, Gospodarowicz MK, Connors JM et al (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National cancer institute of canada clinical trials group and the Eastern cooperative oncology group. J Clin Oncol 23(21):4634–4642

    Article  PubMed  CAS  Google Scholar 

  • Mill WB, Griffith R (1980) The role of radiation therapy in the management of plasma cell tumors. Cancer 45:647–652

    Article  PubMed  CAS  Google Scholar 

  • Miller RW, van de Geijn J, Raubitschek AA, Orr K, Okunieff P, Glatstein E (1995) Dosimetric considerations in treating mediastinal disease with mantle fields: characterization of the dose under mantle blocks. Int J Radiat Oncol Biol Phys 32(4):1083–1095

    Article  PubMed  CAS  Google Scholar 

  • Miller TP, Dahlberg S, Cassady JR et al (1998) Chemotherapy alone compared with chemotherapy plus radiation therapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339:21–26

    Article  PubMed  CAS  Google Scholar 

  • Mundt AJ, Connell PP, Mansur DB (1999) What is the optimal treatment volume in Hodgkin’s disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy? Radiat Oncol Investig 7(6):353–359 2–8

    Article  PubMed  CAS  Google Scholar 

  • Murawski N, Pfreundschuh M (2010) New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 11:1074–1085

    Article  PubMed  CAS  Google Scholar 

  • Murphy SB, Morgan ER, Katzenstein HM, Kletzel M (2003) Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 25(9):684–687

    Article  PubMed  Google Scholar 

  • Naumann R, Beuthien-Baumann B, Reiss A et al (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer 90(3):620–625

    Article  PubMed  CAS  Google Scholar 

  • Neiman RS, Rosen PJ, Lukes RJ (1973) Lymphocyte-depletion Hodgkin’s disease. A clinicopathological entity. N Engl J Med 288(15):751–755

    Article  PubMed  CAS  Google Scholar 

  • Ng AK, Mauch PM (2002) Controversies in early stage Hodgkin’s disease. Oncol (Williston Park) 16(5):588–595 598; Discussion 600, 605, 609–618

    Google Scholar 

  • Nogova L, Reineke T, Eich HT et al (2005) Extended field radiation therapy, combined modality treatment or involved field radiation therapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16(10):1683–1687

    Article  PubMed  CAS  Google Scholar 

  • Nogova L, Reineke T, Brillant C et al (2008) Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26(3):434–439

    Article  PubMed  Google Scholar 

  • Noordijk EM, Thomas J, Fermé C et al (2005) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol, ASCO Ann Meeting Proc 23(No. 16S, Part I of II (June 1 Supplement)):6505

    Google Scholar 

  • Noordijk EM, Carde P, Dupouy N et al (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24(19):3128–3135

    Article  PubMed  Google Scholar 

  • Oberlin O, Leverger G, Pacquement H et al (1992) Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French society of pediatric oncology. J Clin Oncol 10(10):1602–1608

    PubMed  CAS  Google Scholar 

  • Ozsahin M, Tsang RW, Poortmans P et al (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64:210–217

    Article  PubMed  Google Scholar 

  • Pakos EE, Fotopoulos AD, Ioannidis JP (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46(6):958–963

    PubMed  Google Scholar 

  • Palos B, Kaplan HS, Karzmark CJ (1971) The use of thin lung shields to deliver limited whole-lung irradiation during mantle-field treatment of Hodgkin’s disease. Radiol 101(2):441–442

    CAS  Google Scholar 

  • Pavlovsky S, Maschio M, Santarelli MT et al (1988) Randomized trial of chemotherapy versus chemotherapy plus radiation therapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst 80(18):1466–1473

    Article  PubMed  CAS  Google Scholar 

  • Pellegrino B, Terrier-Lacombe MJ, Oberlin O et al (2003) Lymphocyte-predominant Hodgkin’s lymphoma in children: therapeutic abstention after initial lymph node resection—a study of the French Society of Pediatric Oncology. J Clin Oncol 21(15):2948–2952

    Article  PubMed  CAS  Google Scholar 

  • Peters M (1950) A study of survival in Hodgkin’s disease treated radiologically. Am J Roentgenol 63:299–311

    Google Scholar 

  • Peters MV (1966) Prophylactic treatment of adjacent areas in Hodgkin’s disease. Cancer Res 26(6):1232–1243

    PubMed  CAS  Google Scholar 

  • Petrausch U, Samaras P, Veit-Haibach P et al (2010) Hodgkin’s lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 21(5):1053–1057

    Article  PubMed  CAS  Google Scholar 

  • Picardi M, De Renzo A, Pane F et al (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48(9):1721–1727

    Article  PubMed  Google Scholar 

  • Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiation therapy in non-AIDS-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962. J Clin Oncol 21:4483–4488

    Article  PubMed  CAS  Google Scholar 

  • Press OW, LeBlanc M, Lichter AS et al (2001) Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 19(22):4238–4244

    PubMed  CAS  Google Scholar 

  • Prosnitz LR (1990) Hodgkin’s disease: the right dose. Int J Radiat Oncol Biol Phys 19(3):803–804

    Article  PubMed  CAS  Google Scholar 

  • Prosnitz LR, Farber LR, Fischer JJ, Bertino JR (1973) Low dose radiation therapy and combination chemotherapy in the treatment of advanced Hodgkin’s disease. Radiol 107(1):187–193

    CAS  Google Scholar 

  • Raemaekers J, Burgers M, Henry-Amar M et al (1997) Patients with stage III/IV Hodgkin’s disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiation therapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann Oncol 8(Suppl 1):111–114

    Article  PubMed  Google Scholar 

  • Ragni G, Lombardi C, Santoro A, Bestetti O, Wyssling H (1983) Male infertility caused by the chemotherapy of Hodgkin’s disease: MOPP versus ABVD. Acta Eur Fertil 14(3):221–222

    PubMed  CAS  Google Scholar 

  • Roach M 3rd, Kapp DS, Rosenberg SA, Hoppe RT (1987) Radiation therapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol 5(4):550–555

    PubMed  Google Scholar 

  • Rosenberg SA, Kaplan HS (1966) Evidence for an orderly progression in the spread of Hodgkin’s disease. Cancer Res 26(6):1225–1231

    PubMed  CAS  Google Scholar 

  • Ruhl U, Albrecht M, Dieckmann K et al (2001) Response-adapted radiation therapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51(5):1209–1218

    Article  PubMed  CAS  Google Scholar 

  • Schellong G, Bramswig JH, Schwarze EW, Wannenmacher M (1988) An approach to reduce treatment and invasive staging in childhood Hodgkin’s disease: the sequence of the German DAL multicenter studies. Bull Cancer 75(1):41–51

    PubMed  CAS  Google Scholar 

  • Schellong G, Bramswig JH, Hornig-Franz I, Schwarze EW, Potter R, Wannenmacher M (1994) Hodgkin’s disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian pediatric study group. Ann Oncol 5(Suppl 2):113–115

    Article  PubMed  Google Scholar 

  • Schoder H, Meta J, Yap C et al (2001) Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 42(8):1139–1143

    PubMed  CAS  Google Scholar 

  • Senan S, Piet A, Lagerwaard F (2007) Involved-node radiation therapy to the mediastinum. Radiother Oncol 82(1):108–109

    Article  PubMed  Google Scholar 

  • Senff NJ, Noordijk EM, Kim YH et al (2008) European organization for research and treatment of cancer and international society for cutaneous lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609

    Article  PubMed  CAS  Google Scholar 

  • Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78(1):1–5

    Article  PubMed  Google Scholar 

  • Somers R, Tubiana M, Henry-Amar M (1989) EORTC lymphoma cooperative group studies in clinical stage I–II Hodgkin’s disease 1963–1987. Recent Results Cancer Res 117:175–181

    Article  PubMed  CAS  Google Scholar 

  • Spaepen K, Stroobants S, Dupont P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19(2):414–419

    PubMed  CAS  Google Scholar 

  • Specht L, Gray RG, Clarke MJ, Peto R (1998) Influence of more extensive radiation therapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3, 888 patients. International Hodgkin’s disease collaborative group. J Clin Oncol 16(3):830–843

    PubMed  CAS  Google Scholar 

  • van Leeuwen FE, Klokman WJ, Stovall M et al (1995) Roles of radiation therapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 87(20):1530–1537

    Article  PubMed  Google Scholar 

  • Vijayakumar S, Myrianthopoulos LC (1992) An updated dose-response analysis in Hodgkin’s disease. Radiother Oncol 24(1):1–13

    Article  PubMed  CAS  Google Scholar 

  • Viviani S, Bonadonna G, Santoro A et al (1991) Alternating versus hybrid MOPP-ABVD in Hodgkin’s disease: the Milan experience. Ann Oncol 2(Suppl 2):55–62

    Article  PubMed  Google Scholar 

  • Weihrauch MR, Re D, Bischoff S et al (2002) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol 81(1):20–25

    Article  PubMed  CAS  Google Scholar 

  • Weinshel EL, Peterson BA (1993) Hodgkin’s disease. CA Cancer J Clin 43(6):327–346

    Article  PubMed  CAS  Google Scholar 

  • Yahalom J, Varsos G, Fuks Z et al (1993) Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71:2342–2350

    Article  PubMed  CAS  Google Scholar 

  • Young RC, Canellos GP, Chabner BA, Hubbard SM, DeVita VT Jr (1978) Patterns of relapse in advanced Hodgkin’s disease treated with combination chemotherapy. Cancer 42(2 Suppl):1001–1007

    Article  PubMed  CAS  Google Scholar 

  • Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91(4):522–529

    PubMed  Google Scholar 

  • Zinzani PL, Tani M, Trisolini R et al (2007) Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 92(6):771–777

    Article  PubMed  Google Scholar 

  • Zittoun R, Audebert A, Hoerni B et al (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3(2):207–214

    PubMed  CAS  Google Scholar 

  • Zouhair A, Weber D, Belkacémi Y et al (2002) Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 52:652–656

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Therapeutic Radiology – Radiation Oncology, University of Minnesota, Minneapolis, MN, USA

    Chung K. Lee

  2. Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands

    Philip Poortmans

Authors
  1. Chung K. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip Poortmans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Poortmans .

Editor information

Editors and Affiliations

  1. Institutet Stockholm Sweden, MMC 436, Dept.of Oncol-Pathol Karolinska, Delaware St. SE 420, Minneapolis, 55455, Minnesota, USA

    Seymour H. Levitt

  2. UC Davis Cancer Center, Dept. Radiation Oncology, University of California, Davis, X Street 4501, Sacramento, 95817, California, USA

    James A. Purdy

  3. School of Medicine, Dept. Radiation Oncology, Washington University, Forest Park Ave. 4511, St. Louis, 63108-2138, Michigan, USA

    Carlos A. Perez

  4. Instituut Verbeeten, Tilburg, 5042 SB, Netherlands

    Philip Poortmans

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lee, C.K., Poortmans, P. (2011). Radiation Therapy for Hodgkin Lymphoma and Other Hematopoietic Disorders. In: Levitt, S., Purdy, J., Perez, C., Poortmans, P. (eds) Technical Basis of Radiation Therapy. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2011_395

Download citation

  • DOI: https://doi.org/10.1007/174_2011_395

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11571-4

  • Online ISBN: 978-3-642-11572-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation